TPWA
CLDX icon

TRUE Private Wealth Advisors’s Celldex Therapeutics CLDX Stock Holding History

TRUE Private Wealth Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-90
Closed -$1K – 311
2020
Q4 		$1K Hold
90
– – ﹤0.01% 689
2020
Q3 		$1K Buy
+90
New +$1.05K ﹤0.01% 644

Other funds holding CLDX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

TRUE Private Wealth Advisors's CLDX Position: Q1 2021 in Review

TRUE Private Wealth Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2021, closing a stake of 90 shares — an estimated $1K sold.

TRUE Private Wealth Advisors first reported a position in CLDX in Q3 2020 and held it in 2 quarters. The position peaked at $1K in Q4 2020. 115 funds tracked by Wall St. Rank hold CLDX as of Q1 2021.

  • TRUE Private Wealth Advisors reported no remaining Celldex Therapeutics position as of Q1 2021 after selling out during the quarter.
  • TRUE Private Wealth Advisors sold 90 Celldex Therapeutics shares in Q1 2021, an estimated $1K.
  • TRUE Private Wealth Advisors first reported a position in Celldex Therapeutics in Q3 2020 and held it in 2 quarters.
  • TRUE Private Wealth Advisors's Celldex Therapeutics position peaked at $1K in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2021.

Based on TRUE Private Wealth Advisors's 13F filing for Q1 2021, filed 12 May 2021.